SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies

被引：0
|
作者：
Hart, Stefan [1 ]
Goh, Kee Chuan [1 ]
Novotny-Diermayr, Veronica Veronica [1 ]
Tan, Yong Cheng [1 ]
Madan, Babita [1 ]
Amalini, Chithra [1 ]
Loh, Yung Kiang [1 ]
Ong, Lai Chun [1 ]
Williams, Anthony [1 ]
Lee, Angeline [1 ]
Poulsen, Anders [1 ]
Jayaraman, Ramesh [1 ]
Ethirajulu, Kantharaj [1 ]
Dymock, Brian W. [1 ]
Wood, Jeanette M. [1 ]
机构：
[1] S BIO PTE LTD, Singapore, Singapore
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-3570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3570
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
    Komrokji, Rami S.
    Wadleigh, Martha
    Seymour, John F.
    Roberts, Andrew W.
    To, Luen Bik
    Zhu, Huan J.
    Mesa, Ruben A.
    BLOOD, 2011, 118 (21) : 130 - 131
  • [32] Pharmacodynamic (PD) Biomarker Assay Validation for SB1518, a Novel Oral JAK2 Inhibitor in Phase 1 Clinical Trials for Advanced Leukemias, Myeloproliferative Diseases and Lymphoma.
    Hart, Stefan
    Goh, Kee Chuan
    Tan, Yong Cheng
    Chithra, Amalini
    Wood, Jeanette
    BLOOD, 2009, 114 (22) : 750 - 750
  • [33] TG101348: A dual-acting JAK2/FLT3 small molecule kinase inhibitor for the treatment of AML
    Tam, Betty
    Mak, Chi Ching
    Stoughton, Silvia
    Virata, Cyrus
    Lohse, Dan
    Hanna, Ehab
    Alomia, Marcela
    Jamieson, Catriona
    Doukas, John
    Noronha, Glenn
    Martin, Michael
    Soll, Richard
    Hood, John
    BLOOD, 2007, 110 (11) : 274A - 274A
  • [34] GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
    Xinhua Xiao
    Peihong Wang
    Weina Zhang
    Jiayi Wang
    Mansi Cai
    Hua Jiang
    Yingli Wu
    Huizhuang Shan
    Cancer Cell International, 23
  • [35] Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity
    Younes, Anas
    Fanale, Michelle
    McLaughlin, Peter
    Copeland, Amanda R.
    Faria, Silvana de Castro
    Wood, Jeanette
    Ethirajulu, Kantharaj
    Zhu, Huan J.
    BLOOD, 2009, 114 (22) : 244 - 244
  • [36] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [37] The nonclinical toxicology profile of pacritinib, a JAK2/FLT3 inhibitor with no dose-limiting clinical myelosuppression
    Watson, Rebecca
    Al-Fayoumi, Suliman
    CANCER RESEARCH, 2016, 76
  • [38] SAFETY OVERVIEW OF PHASE I-II STUDIES OF PACRITINIB, A NON-MYELOSUPPRESSIVE JAK2/FLT3 INHIBITOR, IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
    Verstovsek, S.
    Liang, S.
    Komrokji, R.
    Mesa, R.
    Seymour, J.
    Dean, J.
    Wang, L.
    Singer, J.
    Myint, H.
    Younes, A.
    HAEMATOLOGICA, 2013, 98 : 119 - 120
  • [39] Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms (Vol 12, 37, 2022)
    Hu, Mengshi
    Yang, Tao
    Yang, Linyu
    Niu, Lu
    Zhu, Jinbing
    Zhao, Ailin
    Shi, Mingsong
    Yuan, Xue
    Tang, Minghai
    Yang, Jianhong
    Pei, Heying
    Yang, Zhuang
    Chen, Qiang
    Ye, Haoyu
    Niu, Ting
    Chen, Lijuan
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [40] LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia
    Yu, Zhou
    Du, Jiaying
    Hui, Hui
    Kan, Shaoxin
    Huo, Tongxin
    Zhao, Kai
    Wu, Tao
    Guo, Qinglong
    Lu, Na
    THERANOSTICS, 2021, 11 (01): : 93 - 106
12345